The primary therapeutic domain for Clopran (clomipramine hydrochloride) is the supportive management of certain distressing symptoms. It is commonly used across conditions presenting with acute episodes. The drug is relevant for managing symptom clusters that may become intense or disruptive. The use is applicable across conditions presenting with a significant symptomatic burden, including Obsessive-Compulsive Disorder (OCD), certain mood disorders, and panic disorder.

Therapeutic Scope and Benefits

In clinical practice, Clopran is applied when appropriate in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations. This is relevant for adults and may be part of symptomatic management in certain pediatric patient groups. It is also used in specialized cases, including to help ease cataplexy (sudden muscle weakness) associated with narcolepsy and to manage certain types of chronic neuropathic pain.

Quick Fact: Relief for Obsessive Symptoms

Clopran plays a role in managing obsessions (recurrent, intrusive thoughts) and compulsions (repetitive, ritualized behaviors) that create noticeable functional strain.

This section summarizes the official population eligibility and non-eligibility criteria for Clopran (Clomipramine Hydrochloride) as defined by governmental regulatory authorities.

Contraindicated Populations

Clopran must not be used in patients with a known hypersensitivity to clomipramine or other tricyclic antidepressants (TCAs) of the dibenzazepine group. It is contraindicated during the acute recovery phase following a myocardial infarction and for patients currently taking, or within 14 days of stopping, a Monoamine Oxidase Inhibitor (MAOI), including agents like linezolid or intravenous methylene blue.

Restricted and Non-Eligible Groups

• Age: Use is established for adults and for children aged 10 years and older for the treatment of Obsessive-Compulsive Disorder (OCD) in the US label. Use in children under 10 years is not established. Older adults (geriatric) are a restricted-use population requiring caution due to increased sensitivity.
• Comorbid Conditions: The medicine is contraindicated in the presence of severe cardiac arrhythmias (e.g., heart block), severe liver disease, and uncontrolled narrow-angle glaucoma. Caution is required for patients with a history of seizure disorders, renal impairment, or urinary retention.
• Pregnancy and Lactation: Use during pregnancy is generally not recommended unless the benefit outweighs the risk to the fetus. The drug is not recommended for mothers who are breastfeeding.

Interactions with other medicines and products

Clopran (Clomipramine Hydrochloride) has officially documented interaction patterns that are defined by government regulatory authorities, primarily categorized by the risk of severe pharmacodynamic or pharmacokinetic outcomes.

Contraindicated Combinations

Co-administration with certain products is strictly prohibited due to high risks such as life-threatening serotonin syndrome or cardiac toxicity.

• Monoamine Oxidase Inhibitors (MAOIs): Formal co-administration is contraindicated. A 14-day separation window is mandatory after stopping an MAOI before starting Clopran, or vice versa.
• Pimozide or Thioridazine: Contraindicated due to the potential for increasing the risk of QTc interval prolongation.
• Other QTc-Prolonging Drugs: Co-administration with other agents known to prolong the QTc interval is prohibited.

Pharmacokinetic and Pharmacodynamic Interactions

Regulatory documents detail exposure-altering interactions, primarily based on the hepatic enzyme system. Inhibitors of the CYP2D6 or CYP1A2 enzymes (e.g., fluoxetine, fluvoxamine) may significantly increase the plasma concentration of Clopran. This effect is also seen in individuals classified as CYP2D6 poor metabolizers and may lead to higher steady-state concentrations in elderly patients.

Additionally, pharmacodynamic synergy is documented with other serotonergic agents, including the herbal product St. John's Wort, due to the additive risk of serotonin syndrome. Formal interaction concerns are also noted with alcohol.

Dual Modulation of Neurotransmitter Pathways

Clopran's mechanism is defined by the reuptake blockade of both the Serotonin Transporter (SERT) (SLC6A4) and the Norepinephrine Transporter (NET) (SLC6A2). This molecular action immediately increases the synaptic availability of Serotonin (5-HT) and Norepinephrine (NE) by preventing their reabsorption into the pre-synaptic neuron. The sustained elevation of these monoamines triggers a long-term adaptive response in key neuronal circuits that modulates their activity. This dual targeting is reinforced by its active metabolite, Desmethylclomipramine, which provides substantial Norepinephrine inhibition, resulting in a balanced, dual-pathway functional enhancement across both major monoamine systems.

---

Non-Selective Receptor Blockade

Beyond monoamine transporters, the drug acts as an antagonist at several non-selective targets, including Histamine H1 and Muscarinic Acetylcholine receptors. This rapid blockade affects signaling pathways governing arousal and autonomic regulation. This concurrent action results in immediate central depressant effects and modulation of smooth muscle tone in peripheral organ systems, which contributes to the overall physiological output alongside its primary reuptake mechanism.

How to Use Clopran (Clomipramine)

The usage of Clopran (clomipramine hydrochloride) is governed by a structured administration protocol, requiring careful progression of the dose and specific timing as detailed in established clinical guidelines. The medicine is primarily available for oral administration as capsules and tablets, but an injectable solution is approved for intravenous (IV) infusion in certain specialized clinical settings.

Administration and Dosage Progression

Treatment is initiated using a low daily dose, such as 25 mg for adults, followed by a process of gradual dose increase (titration) toward a maintenance level. During this initial phase, the dose may be split into divided doses and should be taken with meals to help reduce potential gastrointestinal upset. Once the stable dose is established, the total amount may be taken once daily at bedtime to align with the medication's properties.

Key Usage Parameters

The maximum recommended daily dosage for adults is typically 250 mg. Clinical guidelines require specific dosing modifications for certain populations: older adults must start at a lower dose (e.g., 10 mg or 25 mg daily) and maintain reduced amounts, and specific parameters are set for pediatric patients aged 10 and older. Oral forms must be swallowed whole, and if the course of treatment is to be discontinued, the dosage must be gradually tapered over a period to complete the proper use protocol.

Research evidence / Overview of studies for Clopran

Clopran was studied in a number of clinical trials and systematic reviews examining symptom patterns in specific conditions. The following overview describes the types of studies conducted, what they focused on, and the known limits of the research.

---

Evidence for use in Obsessive-Compulsive Disorder (OCD)

The research base for Clopran in conditions characterized by fluctuating or episodic manifestations like Obsessive-Compulsive Disorder has been evaluated in multiple studies and primarily involves short-term, placebo-controlled clinical trials. Studies monitored changes over defined time intervals, typically 8 to 12 weeks, focusing on outcomes related to symptom intensity or variability, primarily using specialized rating scales like the Y-BOCS. Findings describe patterns observed in the studies where measurements were taken for symptom scores in those receiving the medicine and those receiving placebo. Studies contribute to the broader evidence landscape regarding short-term changes.

Despite the presence of short-term data, there are research limitations. Long-term outcomes are not fully established; evidence is limited regarding the durability of the reported changes beyond the initial few months of follow-up. Furthermore, the core pivotal trials for this indication are now considered historical.

---

Evidence for use in Panic Disorder

Research examined Clopran in conditions associated with acute or disruptive episodes, specifically Panic Disorder. The research base for this use is based on fewer studies than for OCD and includes smaller placebo-controlled and comparative clinical trials. Studies monitored outcomes describing episodic or acute changes, focusing on the frequency and intensity of panic attacks. The data show patterns related to the measured changes in panic attack frequency over the short follow-up durations (typically 6–13 weeks).

---

Research Gaps and Areas of Uncertainty

A major limitation is the historical nature of the core data, meaning many pivotal studies predated contemporary methodologies. Follow-up durations were limited across many trials, leading to insufficient data for long-term outcomes and recurrence prevention. Comparative evidence is lacking against the full range of modern treatments now available. Additionally, subgroup findings are uncertain for many special populations, such as older adults, meaning evidence quality varies across the spectrum of studies.

Key Studies & References

1. National Institute for Health and Care Excellence (NICE): Obsessive-compulsive disorder and body dysmorphic disorder: treatment guidelines

Common questions about Clopran (FAQ)

---

Q: What are the most common side effects of Clopran?

The official product labeling, based on clinical studies, lists common side effects. These frequently reported effects listed in the product information include nausea, headache, and dizziness.

---

Q: Can I drink alcohol while taking Clopran?

Official regulatory information specifically addresses the co-use of alcohol with this product. The official labeling states that alcohol should generally be avoided or notes that caution is advised due to a potential increase in certain effects, such as drowsiness.

---

Q: How should I store Clopran?

Regulatory documents provide specific instructions on how to maintain the quality of the medication. Official guidance indicates that Clopran is intended to be stored at room temperature and kept in a place that is protected from moisture and light to ensure its stability.

---

Q: Is Clopran safe to take during pregnancy?

Official product labeling provides information regarding the use of Clopran during pregnancy. This data is included in the Warnings and Precautions section of the full label, which can be reviewed for specific details.

---

Q: Does Clopran cause drowsiness or affect my ability to drive?

The product labeling acknowledges that adverse reactions such as drowsiness and dizziness can occur. Because of these potential effects, official information indicates that the ability to drive or operate machinery may be potentially impaired.

---

Q: Can children under 12 years old take Clopran?

Official regulatory labeling indicates that the safety and effectiveness of Clopran are generally not established in pediatric patients younger than the age specified in the documentation (e.g., 12 years old).

---

Q: What is the maximum dose I can take in a day?

The maximum recommended amount of the drug within a 24-hour period is specified in the official regulatory documentation. This information is found in the Dosage and Administration section of the full prescribing information.

How to Store and Dispose of Clopran? (Clomipramine Hydrochloride)

Official regulatory guidelines strictly define the storage and disposal requirements for Clopran to ensure product stability and public safety.

---

Storage Conditions

Clomipramine must be stored at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F). The product must be protected from light and excessive moisture, and it should not be frozen. Keep the medicine in its original container, tightly closed.

---

Child Safety and Disposal

This medication must be stored out of the sight and reach of children in a secure location. For unused or expired medicine, regulatory agencies recommend using an authorized drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance, seal it in a bag, and discard it in the household trash. Do not flush Clopran down the toilet or pour it down a drain.